Spots Global Cancer Trial Database for Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Official Title: Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Study ID: NCT00072852
Conditions
Interventions
Study Description
Brief Summary: The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Mobile, Alabama, United States
Pfizer Investigational Site, Anchorage, Alaska, United States
Pfizer Investigational Site, Lewistown, Idaho, United States
Pfizer Investigational Site, Alton, Illinois, United States
Pfizer Investigational Site, Indianapolis, Indiana, United States
Pfizer Investigational Site, Overland Park, Kansas, United States
Pfizer Investigational Site, Chalmette, Louisiana, United States
Pfizer Investigational Site, Covington, Louisiana, United States
Pfizer Investigational Site, Mandeville, Louisiana, United States
Pfizer Investigational Site, Metairie, Louisiana, United States
Pfizer Investigational Site, Metairie, Louisiana, United States
Pfizer Investigational Site, New Orleans, Louisiana, United States
Pfizer Investigational Site, Boston, Massachusetts, United States
Pfizer Investigational Site, Boston, Massachusetts, United States
Pfizer Investigational Site, Boston, Massachusetts, United States
Pfizer Investigational Site, Detroit, Michigan, United States
Pfizer Investigational Site, Southaven, Mississippi, United States
Pfizer Investigational Site, Kansas City, Missouri, United States
Pfizer Investigational Site, St. Louis, Missouri, United States
Pfizer Investigational Site, St. Louis, Missouri, United States
Pfizer Investigational Site, Washington, Missouri, United States
Pfizer Investigational Site, New Brunswick, New Jersey, United States
Pfizer Investigational Site, New Brunswick, New Jersey, United States
Pfizer Investigational Site, New York, New York, United States
Pfizer Investigational Site, Stony Brook, New York, United States
Pfizer Investigational Site, Kettering, Ohio, United States
Pfizer Investigational Site, Oklahoma City, Oklahoma, United States
Pfizer Investigational Site, Greenville, South Carolina, United States
Pfizer Investigational Site, Covington, Tennessee, United States
Pfizer Investigational Site, Franklin, Tennessee, United States
Pfizer Investigational Site, Gallatin, Tennessee, United States
Pfizer Investigational Site, Hermitage, Tennessee, United States
Pfizer Investigational Site, Lebanon, Tennessee, United States
Pfizer Investigational Site, Memphis, Tennessee, United States
Pfizer Investigational Site, Murfreesboro, Tennessee, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Dallas, Texas, United States
Pfizer Investigational Site, Dallas, Texas, United States
Pfizer Investigational Site, Dallas, Texas, United States
Pfizer Investigational Site, Dallas, Texas, United States
Pfizer Investigational Site, Fort Worth, Texas, United States
Pfizer Investigational Site, Plano, Texas, United States
Pfizer Investigational Site, Tyler, Texas, United States
Pfizer Investigational Site, Federal Way, Washington, United States
Pfizer Investigational Site, Lakewood, Washington, United States
Pfizer Investigational Site, Seattle, Washington, United States
Pfizer Investigational Site, Seattle, Washington, United States
Pfizer Investigational Site, Seattle, Washington, United States
Pfizer Investigational Site, Seattle, Washington, United States
Pfizer Investigational Site, Seattle, Washington, United States
Pfizer Investigational Site, Tacoma, Washington, United States
Pfizer Investigational Site, Vancouver, Washington, United States
Pfizer Investigational Site, Yakima, Washington, United States
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina
Pfizer Investigational Site, Rosario, Santa Fe, Argentina
Pfizer Investigational Site, Capital Federal, , Argentina
Pfizer Investigational Site, Cordoba, , Argentina
Pfizer Investigational Site, Santa Fe, , Argentina
Pfizer Investigational Site, South Brisbane, Queensland, Australia
Pfizer Investigational Site, Frankston, Victoria, Australia
Pfizer Investigational Site, Bogota, Bogota DC, Colombia
Pfizer Investigational Site, Wellington, , New Zealand
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
